These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29781563)

  • 1. Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia.
    Løhmann DJA; Asdahl PH; Abrahamsson J; Ha SY; Jónsson ÓG; Kaspers GJL; Koskenvuo M; Lausen B; De Moerloose B; Palle J; Zeller B; Hasle H
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27231. PubMed ID: 29781563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01.
    Løhmann DJA; Asdahl PH; Abrahamsson J; Ha SY; Jónsson ÓG; Kaspers GJL; Koskenvuo M; Lausen B; De Moerloose B; Palle J; Zeller B; Hasle H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27701. PubMed ID: 30848067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.
    Sung L; Aplenc R; Alonzo TA; Gerbing RB; Wang YC; Meshinchi S; Gamis AS
    Int J Cancer; 2016 Nov; 139(9):1930-5. PubMed ID: 27312107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
    De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
    Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
    Gerbing RB; Alonzo TA; Sung L; Gamis AS; Meshinchi S; Plon SE; Bertuch AA; Gramatges MM
    J Clin Oncol; 2016 Nov; 34(31):3766-3772. PubMed ID: 27354474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Efficacy of NOPHO-AML 2004 Regimen for Treatment of Children with Acute Myelocytic Leukemia (Non-M3)].
    Qiu KY; Liao XY; Huang K; Li Y; Weng WJ; Xu HG; Fang JP; Wu RH; Zhou DH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):375-381. PubMed ID: 29665901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
    Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia.
    Molgaard-Hansen L; Möttönen M; Glosli H; Jónmundsson GK; Abrahamsson J; Hasle H;
    Br J Haematol; 2011 Mar; 152(5):623-30. PubMed ID: 21241281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
    Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
    Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
    J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of early treatment response in children with acute myeloid leukemia].
    Tie LJ; Gu LJ; Song DL; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J; Wang YP; Zou JY
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1837-40. PubMed ID: 17054861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution.
    Sanz MA; de la Rubia J; Sanz GF; Martín G; Martínez J; Jarque I; Sempere A; Gomis F; Senent L; Soler MA
    J Clin Oncol; 1993 Sep; 11(9):1661-7. PubMed ID: 8102640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in overweight and underweight children with acute myeloid leukemia.
    Lange BJ; Gerbing RB; Feusner J; Skolnik J; Sacks N; Smith FO; Alonzo TA
    JAMA; 2005 Jan; 293(2):203-11. PubMed ID: 15644547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
    Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
    Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.